NEOGENOMICS, INC. (NEO) FY2026 YTD Q2 P&L / Income Statement

NEOGENOMICS, INC. (NEO) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

NET REVENUE

388,328,000 US dollars

COST OF REVENUE

215,586,000 US dollars

GROSS PROFIT

172,742,000 US dollars

Total operating expenses

200,754,000 US dollars

LOSS FROM OPERATIONS

negative 28,012,000 US dollars

Other income (expense), net (calculated)

12,260,000 US dollars

Income (loss) before taxes

negative 15,752,000 US dollars

Income tax benefit

negative 884,000 US dollars

Net income (loss)

negative 14,868,000 US dollars

Client direct billing

269,545,000 US dollars

Commercial insurance

67,211,000 US dollars

Medicare and other government

51,572,000 US dollars

Self-pay

0 US dollars

General and administrative

129,354,000 US dollars

Research and development

20,295,000 US dollars

Sales and marketing

51,105,000 US dollars

Impairment charges (Note 5)

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.